The future is #FactorXI. Watch this video featuring Dr. Christian Ruff, where he explains the overwhelmingly positive significance of the AZALEA-TIMI 71 results. He discusses the promise of abelacimab, a novel monoclonal antibody and dual-acting Factor XI/XIa inhibitor, and potential future treatment options for patients with #afib. #atrialfibrillation #afibawareness #strokeawareness #thrombosis #hemostasis #anticoagulant #anticoagulation
Christian Ruff presents: abelacimab, a novel factor XI/XIa inhibitor, vs rivaroxaban inpPatients with atrial fibrillation: primary results of the AZALEA-TIMI 71 trial. #AHA23 #ESCTVOnTheRoad #cardiology #cardiovascular
Clinical Trial Ambassadors and Community Clinical Trial Liaisons, Sr. Director North America |Pharmaceutical Leadership
10moThis is an exciting time for the anticoagulants and certainly promising for those still deemed unsuitable for current standard of care.